With the advent of modern polychemotherapy and radiation techniques, cure rates in Hodgkin's disease (HD) have improved substantially. This article summarises current concepts of treatment for early, intermediate and advanced stage HD. Current strategies focus on the balance between cure rate and toxicity. In early stages, cure rates approach 90% and new strategies mainly try to avoid toxicities. Possible approaches comprise the use of less CT or RT or leaving laparotomy. In advanced stages, polychemotherapy with 8 courses of either M(C)OPP or ABVD or M(CPPP/ABVD is considered to be the treatment of choice, but unsatisfactory low complete remission rates, progression-free survival or freedom from treatment failure rates have to be improved. The role of additional radiotherapy after extensive chemotherapy in the treatment of advanced stages is uncertain. To achieve a better tumour control, new regimens have been developed. The Stanford group initiated the 12-week intensified hybrid protocol Stanford V. The German Hodgkin's Lymphoma Study Group (GHSG) introduced the BEACOPP protocol with time intensification and dose escalation of cyclophosphamide and etoposide. The Milan Cancer Institute tries to improve treatment outcome using high doses of single agents. One problem to be addressed in ongoing and future trials is the identification of high-risk groups allowing an early stratification of patients into more agressive but effective regimens. Risk-adapted therapy might allow further reduction of doses in patients with early-stage Hodgkin's disease.
Introduction
Hodgkin's disease was fatal until the development of radiation techniques and polychemotherapy. Over the last 25 years, a large number of clinical trials have substantially contributed to the rapid improvement in the management of this disease. Here, we summarize the current clinical trials in patients with newly diagnosed Hodgkin's disease separately for early/intermediate stages and advanced stages.
Early and intermediate stages
The long-term disease-free survival in early-stage Hodgkin's lymphoma approaches 90%. Since it seems unlikely to further improve treatment results substantially beyond this level, a major goal for this group of patients is the reduction of acute and long-term toxicity. The impressive treatment results further imply that many Hodgkin's patients might be overtreated. Second malignancies including solid tumours, acute leukemias and non-Hodgkin's lymphoma have been reported in up to 17% of patients after 15 years [1] . Combined modality treatment involving MOPP-based regimen and radiotherapy are associated with a higher incidence of solid tumours. Reducing overall toxicity can be achieved by reduction of both radiotherapy and chemotherapy. The question of optimal dose and volume of radiotherapy is still a matter of discussion. As far as the best chemotherapy regimen is concerned, one promising approach in early and intermediate stage Hodgkin's lymphoma is to identify cytostatic drugs that are both highly effective and less carcinogenic.
Another important issue which might help to avoid overtreatment is a better definition of risk factors, which has to be investigated in current and future clinical trials.
Staging laparotomy
Staging laparotomy for early-stage Hodgkin's lymphoma is still under discussion. The H6 trial of the EORTC [2] demonstrated that in early stages laparotomy can be omitted without compromising treatment outcome. In 25%-30% of patients with supradiaphragmatic early stages, occult infradiaphragmatic involvement, undetectable by ultrasound or CT scans, is detected during laparotomy. Thus, laparotomy is still the most precise method to identify occult lesions in the abdomen. However, this procedure is also associated with side effects such as severe bacterial infections and blood loss. The introduction of chemotherapy in early-stage Hodgkin's disease might become a means to control occult abdominal involvement without prior laparotomy. One example of a trial testing this hypothesis is the Stanford Gl trial [3] 
Radiotherapy alone
Patients with mediastinal involvement only or women in clinical stage IA and LP histology seem to have a significantly lower risk for infradiaphragmatic involvement. This very favourable group of patients can be treated with mantle field or extended field radiation without staging laparotomy [4] . This concept was followed in three different trials performed by the EORTC [5] , Stanford [6] , and Harvard JCRT [7] (Table  1) . Unfortunately, this subgroup of patients represents less than 10% of all Hodgkin's patients. The majority of 90% of Hodgkin patients in localised or intermediate stages are treated with extended field (EF) radiation or combined modality approaches.
Comparison of radiotherapy with chemotherapy alone
Two other studies have compared radiotherapy with chemotherapy alone. The NCI-USA [8] compared 6 x MOPP with chemotherapy alone in 106 patients. The results in the MOPP arm were significantly better. Biti et al. [9] compared 6 x MOPP with EF radiotherapy in 89 patients. The complete remission and relapse rates were very similar in both arms. The overall sur- vival was 56% for the MOPP-treated patients, compared with 93% in the EF group. The unexpectedly large difference in survival between the two arms was mainly due to better results of salvage therapy in the radiotherapy arm.
Comparison of radiotherapy with combined modality treatment
A recent overview by Specht et al. [10] including more than 20 randomized trials compared radiotherapy alone with combined modality treatment. Relapse-free survival was better with combined modality treatment but the overall survival was comparable in both groups. This is probably due to superior salvage results with chemotherapy in patients pretreated with radiotherapy only. One example of a current clinical trial comparing radiotherapy with combined modality treatment is the H8 trial of the EORTC [11] : in favourable subgroups, subtotal nodal plus spleen irradiation is compared with 3 courses MOPP/ABV plus IF irradiation. For the same group of patients, the previous EORTC trial-H7 [12] had demonstrated a higher relapse-free survival and freedom from progression for combined modality treatment with 6 courses of EBVP plus IF as compared with subtotal nodal irradiation although there was no difference in terms of survival. The ROME study group [13] reported better results with one cycle ABVD plus subtotal nodal radiation (STNI) compared with STNI alone. Other examples of similar ongoing studies are the NCI Canada trial [14] , in which radiotherapy alone is compared with 2 courses of ABVD plus STNI, the GHSG HD7 trial [15] , evaluating EF radiotherapy or 2 courses ABVD plus EF, and the BNLI trial [16] , in which patients are randomized between one month of VAPEC-B chemotherapy plus IF or mantle field radiation alone (Table 2) . Shore et al. [17] performed a metaanalysis of 23 publications including 2999 patients, comparing EF or EF radiotherapy and combined modality treatment. The relapse-free survival rate was significantly better in the combined modality-treated group, followed by EF and IF radiotherapy. However, there was no significant difference in the overall survival. Thus, further observation to finally judge the long-term results and late toxicities is needed. [20] analyses a response-adapted strategy in the ongoing HD-6-ECOG-IHDO6 trial by comparing three groups treated either with radiotherapy alone, 2 x ABVD plus irradiation or 2 x ABVD plus 2-4 additional cycles of ABVD (4-6 total) depending upon response.
Advanced-stage Hodgkin's lymphoma
Polychemotherapy with 8 courses of either MOPP or ABVD is considered the treatment of choice for patients with advanced Hodgkin's lymphoma [20] [21] [22] . The complete remission rate of the 'gold standard' is about 75%, with freedom from treatment failure rates of 50% after 5 years. So far, several international multicenter trials have been unable to obtain superior results by replacing drugs from the MOPP/ABVD protocol. Many study groups prefer ABVD instead of MOPP or MOPP/ABVD because of reduced hematological and gonadal toxicity [23] . The most important goal in this group of patients still remains to improve outcome since long-term remission rates are still unsatisfactory. A summary of clinical trials in advanced HD is given in Table 3 .
The role of additional radiotherapy
The role of additional radiotherapy in the treatment of advanced stages is uncertain. The South-West Oncology group (SWOG) randomised patients to receive either radiotherapy or nothing after three courses of MOPP/ABV. The role of additional radiotherapy is currently being further investigated by means of an overview of the international database on Hodgkin's disease (IDHD) [26] .
Time intensification
can improve treatment results over the 'gold standard' in a multicenter setting. G-CSF is used to reduce neutropenia and allow application on time. In this trial, BEACOPP, in a basic and in an escalated version is compared with the standard arm of 4 x COPP/ABVD ( Figure 1 ).
In May 1989 the Stanford group [27] initiated a trial with a 12-week short-term hybrid protocol termed Stanford V. The cytostatic drugs in this protocol are given in 3 cycles of 4 weeks each (Table 4) , followed by consolidative radiotherapy to sites of initial bulky disease. This treatment was well tolerated in 94 patients reported. With a median follow-up of three years, the freedom from progression (FFP) rate is 89% and survival 93%. This seems to indicate that the Stanford V regimen is effective in advanced stages. The lower cumulative dose of alkylating agents might reduce the long-term side effects in terms of fertility. In addition, the reduction of radiation volume in this protocol might further decrease the risk of second neoplasias and cardiopulmonary toxicity. The Stanford V regimen is investigated by the ECOG (Eastern Cooperative Oncology Group) in a multicenter setting.
Dose escalation
In the HD9 study of the GHSG [28] , a new protocol, BEACOPP, consisting of bleomycine, etoposide, adriamycine, cyclophosphamide, vincristine, procarbazine and prednisone (Table 5 ) is introduced to test whether dose escalation for cyclophosphamide and etoposide Figure 1 . HD-9 protocol of the GHSG. (day 1; 45; 90), vincristine (day 1; 45; 90), prednisone (day 1-5; 45-49; 90-94), cyclophosphamid (day 15; 60), and VP-16 (day 30; 75). The drugs are applied at 14-day intervals followed by radiotherapy from day 118 on (Table 6 ). So far, 48 previously untreated patients with stages HB-IV have been reported. The treatment was well tolerated and effective resulting in complete remissions in 75% of patients after chemotherapy and 94% after radiotherapy.
Conclusion and prospects
Clinical trials in Hodgkin's disease have contributed substantially to the high diagnostic and therapeutic standard in this disease. Still, many questions remain unsolved. The most obvious problems to be addressed in ongoing and future trials are the identification of risk groups possibly allowing for an early stratification of patients into more agressive approaches. There are several possible means to treat high-risk patients including upfront high-dose regimens. On the other hand, a risk-adapted therapy might help to reduce doses of both radiotherapy and chemotherapy in patients with favourable risk factors.
